Highest-materiality recent filing
RenovoRx Q2 revenue $909k, up 115% YoY; raises FY26 guidance to $3.75-4.25M
Q2 2026 revenue $909k, up 61% QoQ and 115% YoY; gross margin 84.3%.
RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M
Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.
RenovoRx receives Nasdaq extension to Dec 28, 2026 to regain $1 minimum bid price compliance
Received Nasdaq notice on July 1, 2026 granting additional 180-day compliance period until Dec 28, 2026.
RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M
Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.
FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.
RenovoRx raises $10M via common stock and milestone warrants in oversubscribed offering
Raised ~$10M gross from sale of 8.4M shares, 2.2M pre-funded warrants, and 5.3M milestone warrants to 15 investors (including insiders).
Mark Voll, age 72, appointed CFO effective Feb 4, 2026; also serves as Principal Financial and Accounting Officer.
RenovoRx receives Nasdaq deficiency notice for minimum bid price non-compliance
Received Nasdaq notice Dec 31, 2025; closing bid price below $1.00 for 32 consecutive business days.
RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers
Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.
RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial
Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.
RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized
Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.
RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled
First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.
RenovoRx prices $12.1M underwritten public offering of 11.5M shares at $1.05 per share
Offering of 11,523,810 shares at $1.05/share; gross proceeds ~$12.1M, net ~$10.9M after underwriting discounts and expenses.
RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025
Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.
RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.
RenovoRx auditor Baker Tilly to resign; CEO salary restored with bonuses after $17.2M equity raise
Baker Tilly resigns as auditor effective after Q2 2024 10-Q filing (expected Aug 2024); no accounting disagreements.
RenovoRx regains Nasdaq compliance after $17.2M fundraising; hearing cancelled
Nasdaq confirmed RenovoRx met $2.5M minimum stockholders' equity requirement; prior deficiency remedied.
RenovoRx raises $11.1M, believes it has regained Nasdaq equity compliance
Closed $11.1M private placement of common stock and warrants on April 11, 2024.
RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026
Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.
RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026
Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.
Nasdaq notified RenovoRx on Feb 21, 2024 that it failed minimum stockholders' equity of $2.5M; delisting proceedings to begin unless hearing requested.
RenovoRx closes $6.1M private placement; insider participation; exec salary cuts 25%
Raised gross proceeds of $6,111,695 via private placement of 6,133,414 shares + warrants at $0.99/share (non-insiders) and $1.22 (insiders).
RenovoRx gets Nasdaq extension to Feb 19, 2024 for $2.5M equity compliance
Nasdaq granted extension to February 19, 2024 to meet $2.5M stockholders' equity requirement (Rule 5550(b)(2)).
RenovoRx receives Nasdaq delisting notice for equity below $2.5M minimum
Stockholders' equity of $1,188,000 as of June 30, 2023, below Nasdaq's $2.5M minimum requirement.
RenovoRx Q2 net loss $2.3M; positive Phase III data shows 8-month progression delay
Net loss $2.3M vs $2.6M year ago; cash $6.0M; R&D $1.9M, G&A $1.4M.
Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.
RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit
Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.
RenovoRx raises $5M in registered direct offering and private placement of common stock and warrants
Gross proceeds of ~$5M from sale of 1,557,632 shares (or pre-funded warrants) at $3.21 per share.
RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered
Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).
RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP
In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.
RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022
Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.
On February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.
On February 22, 2024, the Company’s board of directors (the “Board”), by unanimous written consent to action, appointed Leesa Gentry, the Company’s current Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company, effective March 1, 2024.
On February 16, 2024, Angela Gill Nelms provided written notice to the Company of her resignation as the Company’s Chief Operating Officer, effective March 1, 2024.
On February 8, 2024, the Company’s board of directors (the “Board”), at the recommendation of the audit and compensation committees of the Board, appointed Ronald B. Kocak, CPA, CGMA, the Company’s current Vice President and Controller, to the position of Vice President, Controller and Principal Accounting Officer.
On February 5, 2024, James Ahlers provided written notice to RenovoRx, Inc. (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective immediately.
Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director
The Board of Directors of RenovoRx, Inc. (the “Company”) has appointed Ms. Angela Gill Nelms, age 47, as Chief Operating Officer, effective September 19, 2022, her start date with the Company.
The Company’s Board of Directors has appointed Mr. James Ahlers, age 58, as Chief Financial Officer, Secretary and Treasurer, as of July 15, 2022.
Christopher J. Lehman notified RenovoRx, Inc. (the “Company”) of his decision to resign as Chief Financial Officer, effective July 15, 2022.
Max materiality 0.85 · Median 0.60 · Most common event other_material